Clinical Trial

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Study acronym: SELECT-CAR-NK
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-08.
Trial Details
NCT Number NCT07410494
Lead Sponsor Essen Biotech
Conditions Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate Cancer - Recurrent, Pancreatic Ductal Adenocarcinoma (PDAC), Ovarian Cancer, Glioblastoma +5 more
Enrollment 85 participants
Start Date 2026-02-01
Primary Completion 2027-12-28 (estimated)
Study Completion 2028-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-18